-
1
-
-
84860468095
-
Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling
-
Appenzeller-Herzog C., Hall M.N. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol. 2012, 22:274-282.
-
(2012)
Trends Cell Biol.
, vol.22
, pp. 274-282
-
-
Appenzeller-Herzog, C.1
Hall, M.N.2
-
2
-
-
40949128188
-
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
-
Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., Wadleigh M., Ballen K.K., McAfee S., Miller K.B., Levine J., Galinsky I., Trehu E.G., Schenkein D., Neuberg D., Stone R.M., Amrein P.C. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin. Cancer Res. 2008, 14:1446-1454.
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 1446-1454
-
-
Attar, E.C.1
De Angelo, D.J.2
Supko, J.G.3
D'Amato, F.4
Zahrieh, D.5
Sirulnik, A.6
Wadleigh, M.7
Ballen, K.K.8
McAfee, S.9
Miller, K.B.10
Levine, J.11
Galinsky, I.12
Trehu, E.G.13
Schenkein, D.14
Neuberg, D.15
Stone, R.M.16
Amrein, P.C.17
-
3
-
-
43749103819
-
Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation
-
Bai Y., Ahmad U., Wang Y., Li J.H., Choy J.C., Kim R.W., Kirkiles-Smith N., Maher S.E., Karras J.G., Bennett C.F., Bothwell A.L., Pober J.S., Tellides G. Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation. J.Biol. Chem. 2008, 283:6832-6842.
-
(2008)
J.Biol. Chem.
, vol.283
, pp. 6832-6842
-
-
Bai, Y.1
Ahmad, U.2
Wang, Y.3
Li, J.H.4
Choy, J.C.5
Kim, R.W.6
Kirkiles-Smith, N.7
Maher, S.E.8
Karras, J.G.9
Bennett, C.F.10
Bothwell, A.L.11
Pober, J.S.12
Tellides, G.13
-
4
-
-
0025224140
-
Phase I trial of dipyridamole with 5-fluorouracil and folinic acid
-
Budd G.T., Jayaraj A., Grabowski D., Adelstein D., Bauer L., Boyett J., Bukowski R., Murthy S., Weick J. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res. 1990, 50:7206-7211.
-
(1990)
Cancer Res.
, vol.50
, pp. 7206-7211
-
-
Budd, G.T.1
Jayaraj, A.2
Grabowski, D.3
Adelstein, D.4
Bauer, L.5
Boyett, J.6
Bukowski, R.7
Murthy, S.8
Weick, J.9
-
5
-
-
79951702955
-
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives
-
Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 2011, 11:239-253.
-
(2011)
Curr. Cancer Drug Targets
, vol.11
, pp. 239-253
-
-
Chen, D.1
Frezza, M.2
Schmitt, S.3
Kanwar, J.4
Dou, Q.P.5
-
6
-
-
75949105922
-
The Bcl-2 family reunion
-
Chipuk J.E., Moldoveanu T., Llambi F., Parsons M.J., Green D.R. The Bcl-2 family reunion. Mol. Cell. 2010, 37:299-310.
-
(2010)
Mol. Cell.
, vol.37
, pp. 299-310
-
-
Chipuk, J.E.1
Moldoveanu, T.2
Llambi, F.3
Parsons, M.J.4
Green, D.R.5
-
7
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
-
Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme. Regul. 1984, 22:27-55.
-
(1984)
Adv. Enzyme. Regul.
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
9
-
-
0028332080
-
The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance
-
Clarke W.R., Uezono S., Chambers A., Doepfner P. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol. 1994, 7:81-89.
-
(1994)
Pulm. Pharmacol.
, vol.7
, pp. 81-89
-
-
Clarke, W.R.1
Uezono, S.2
Chambers, A.3
Doepfner, P.4
-
10
-
-
84876348206
-
Total cost comparison in relapsed/refractory multiple myeloma
-
Durie B., Binder G., Pashos C., Khan Z., Hussein M., Borrello I. Total cost comparison in relapsed/refractory multiple myeloma. J.Med. Econ. 2013, 16:614-622.
-
(2013)
J.Med. Econ.
, vol.16
, pp. 614-622
-
-
Durie, B.1
Binder, G.2
Pashos, C.3
Khan, Z.4
Hussein, M.5
Borrello, I.6
-
11
-
-
33749252583
-
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
-
Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006, 7:988-994.
-
(2006)
EMBO Rep.
, vol.7
, pp. 988-994
-
-
Eckelman, B.P.1
Salvesen, G.S.2
Scott, F.L.3
-
12
-
-
44449102684
-
Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole
-
Goda A.E., Yoshida T., Horinaka M., Yasuda T., Shiraishi T., Wakada M., Sakai T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008, 27:3435-3445.
-
(2008)
Oncogene
, vol.27
, pp. 3435-3445
-
-
Goda, A.E.1
Yoshida, T.2
Horinaka, M.3
Yasuda, T.4
Shiraishi, T.5
Wakada, M.6
Sakai, T.7
-
13
-
-
84878850784
-
Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor
-
Goda A.E., Koyama M., Sowa Y., Elokely K.M., Yoshida T., Kim B.Y., Sakai T. Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor. Biochem. Pharmacol. 2013, 85:1741-1752.
-
(2013)
Biochem. Pharmacol.
, vol.85
, pp. 1741-1752
-
-
Goda, A.E.1
Koyama, M.2
Sowa, Y.3
Elokely, K.M.4
Yoshida, T.5
Kim, B.Y.6
Sakai, T.7
-
14
-
-
84861567265
-
Redox signaling loops in the unfolded protein response
-
Higa A., Chevet E. Redox signaling loops in the unfolded protein response. Cell. Signal. 2012, 24:1548-1555.
-
(2012)
Cell. Signal.
, vol.24
, pp. 1548-1555
-
-
Higa, A.1
Chevet, E.2
-
15
-
-
0035925098
-
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects
-
Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J.Natl. Cancer Inst. 2001, 93:266-276.
-
(2001)
J.Natl. Cancer Inst.
, vol.93
, pp. 266-276
-
-
Hockel, M.1
Vaupel, P.2
-
16
-
-
33947362982
-
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study
-
Horton T.M., Pati D., Plon S.E., Thompson P.A., Bomgaars L.R., Adamson P.C., Ingle A.M., Wright J., Brockman A.H., Paton M., Blaney S.M. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin. Cancer Res. 2007, 13:1516-1522.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1516-1522
-
-
Horton, T.M.1
Pati, D.2
Plon, S.E.3
Thompson, P.A.4
Bomgaars, L.R.5
Adamson, P.C.6
Ingle, A.M.7
Wright, J.8
Brockman, A.H.9
Paton, M.10
Blaney, S.M.11
-
17
-
-
0022900617
-
Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates
-
Kennedy D.G., Van den Berg H.W., Clarke R., Murphy R.F. Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates. Biochem. Pharmacol. 1986, 35:3053-3056.
-
(1986)
Biochem. Pharmacol.
, vol.35
, pp. 3053-3056
-
-
Kennedy, D.G.1
Van den Berg, H.W.2
Clarke, R.3
Murphy, R.F.4
-
18
-
-
13944274500
-
Mcl-1 regulation and its role in multiple myeloma
-
Le Gouill S., Podar K., Harousseau J.L., Anderson K.C. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004, 3:1259-1262.
-
(2004)
Cell Cycle
, vol.3
, pp. 1259-1262
-
-
Le Gouill, S.1
Podar, K.2
Harousseau, J.L.3
Anderson, K.C.4
-
19
-
-
83255192206
-
BID binds to replication protein A and stimulates ATR function following replicative stress
-
Liu Y., Vaithiyalingam S., Shi Q., Chazin W.J., Zinkel S.S. BID binds to replication protein A and stimulates ATR function following replicative stress. Mol. Cell Biol. 2011, 31:4298-4309.
-
(2011)
Mol. Cell Biol.
, vol.31
, pp. 4298-4309
-
-
Liu, Y.1
Vaithiyalingam, S.2
Shi, Q.3
Chazin, W.J.4
Zinkel, S.S.5
-
20
-
-
53049083867
-
Mechanisms of proteasome inhibitor action and resistance in cancer
-
McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug. Resist. Updat. 2008, 11:164-179.
-
(2008)
Drug. Resist. Updat.
, vol.11
, pp. 164-179
-
-
McConkey, D.J.1
Zhu, K.2
-
21
-
-
42449146501
-
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
-
McCubrey J.A., Steelman L.S., Abrams S.L., Bertrand F.E., Ludwig D.E., Bäsecke J., Libra M., Stivala F., Milella M., Tafuri A., Lunghi P., Bonati A., Martelli A.M. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22:708-722.
-
(2008)
Leukemia
, vol.22
, pp. 708-722
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
Bertrand, F.E.4
Ludwig, D.E.5
Bäsecke, J.6
Libra, M.7
Stivala, F.8
Milella, M.9
Tafuri, A.10
Lunghi, P.11
Bonati, A.12
Martelli, A.M.13
-
22
-
-
0031614916
-
Simultaneous measurement of cell cycle and apoptotic cell death
-
Moore A., Donahue C.J., Bauer K.D., Mather J.P. Simultaneous measurement of cell cycle and apoptotic cell death. Methods Cell Biol. 1998, 57:265-278.
-
(1998)
Methods Cell Biol.
, vol.57
, pp. 265-278
-
-
Moore, A.1
Donahue, C.J.2
Bauer, K.D.3
Mather, J.P.4
-
23
-
-
18244432009
-
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
-
Neubauer H., Cumano A., Müller M., Wu H., Huffstadt U., Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
-
(1998)
Cell
, vol.93
, pp. 397-409
-
-
Neubauer, H.1
Cumano, A.2
Müller, M.3
Wu, H.4
Huffstadt, U.5
Pfeffer, K.6
-
24
-
-
0009975004
-
Mutation of Bcl-2 family proteins in Cancer
-
Packham G. Mutation of Bcl-2 family proteins in Cancer. Apoptosis 1998, 3:75-82.
-
(1998)
Apoptosis
, vol.3
, pp. 75-82
-
-
Packham, G.1
-
25
-
-
30144442233
-
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
-
Pérez-Galán P., Roué G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
-
(2006)
Blood
, vol.107
, pp. 257-264
-
-
Pérez-Galán, P.1
Roué, G.2
Villamor, N.3
Montserrat, E.4
Campo, E.5
Colomer, D.6
-
26
-
-
33646595660
-
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling
-
Piwocka K., Vejda S., Cotter T.G., O'Sullivan G.C., McKenna S.L. Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling. Blood 2006, 107:4003-4010.
-
(2006)
Blood
, vol.107
, pp. 4003-4010
-
-
Piwocka, K.1
Vejda, S.2
Cotter, T.G.3
O'Sullivan, G.C.4
McKenna, S.L.5
-
27
-
-
77956108780
-
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
-
Reddy N., Czuczman M.S. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann. Oncol. 2010, 21:1756-1764.
-
(2010)
Ann. Oncol.
, vol.21
, pp. 1756-1764
-
-
Reddy, N.1
Czuczman, M.S.2
-
28
-
-
42049083776
-
JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors
-
Reuther G.W. JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors. Cell Cycle 2008, 7:714-719.
-
(2008)
Cell Cycle
, vol.7
, pp. 714-719
-
-
Reuther, G.W.1
-
29
-
-
2442600292
-
Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells invitro
-
Rodrigues M., Barbosa F., Perussi J.R. Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells invitro. Braz. J. Med. Biol. Res. 2004, 37:591-599.
-
(2004)
Braz. J. Med. Biol. Res.
, vol.37
, pp. 591-599
-
-
Rodrigues, M.1
Barbosa, F.2
Perussi, J.R.3
-
30
-
-
0015526135
-
Cyclic 3'5'-adenosine monophosphate in human blood platelets: regulatory role of cyclic AMP in platelet function
-
Salzman E.W., Kensler P.C., Levine L. Cyclic 3'5'-adenosine monophosphate in human blood platelets: regulatory role of cyclic AMP in platelet function. Ann. N. Y. Acad. Sci. 1972, 201:61-71.
-
(1972)
Ann. N. Y. Acad. Sci.
, vol.201
, pp. 61-71
-
-
Salzman, E.W.1
Kensler, P.C.2
Levine, L.3
-
31
-
-
0027363244
-
Differentially potentiating effects by dipyridamole on cytotoxicity of 5-fluorouracil against three human maxillary cancer cell lines derived from a single tumor
-
Sato S., Kohno K., Hidaka K., Hisatsugu T., Kuwano M., Komiyama S. Differentially potentiating effects by dipyridamole on cytotoxicity of 5-fluorouracil against three human maxillary cancer cell lines derived from a single tumor. Anticancer. Drug. Des. 1993, 8:289-297.
-
(1993)
Anticancer. Drug. Des.
, vol.8
, pp. 289-297
-
-
Sato, S.1
Kohno, K.2
Hidaka, K.3
Hisatsugu, T.4
Kuwano, M.5
Komiyama, S.6
-
32
-
-
84872682998
-
Dipyridamole prevents triple-negative breast-cancer progression
-
Spano D., Marshall J.C., Marino N., De Martino D., Romano A., Scoppettuolo M.N., Bello A.M., Di Dato V., Navas L., De Vita G., Medaglia C., Steeg P.S., Zollo M. Dipyridamole prevents triple-negative breast-cancer progression. Clin. Exp. Metastasis 2013, 30:47-68.
-
(2013)
Clin. Exp. Metastasis
, vol.30
, pp. 47-68
-
-
Spano, D.1
Marshall, J.C.2
Marino, N.3
De Martino, D.4
Romano, A.5
Scoppettuolo, M.N.6
Bello, A.M.7
Di Dato, V.8
Navas, L.9
De Vita, G.10
Medaglia, C.11
Steeg, P.S.12
Zollo, M.13
-
33
-
-
79951832885
-
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia
-
Tanturli M., Giuntoli S., Barbetti V., Rovida E., Dello Sbarba P. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One 2011, 6:e17008.
-
(2011)
PLoS One
, vol.6
, pp. e17008
-
-
Tanturli, M.1
Giuntoli, S.2
Barbetti, V.3
Rovida, E.4
Dello Sbarba, P.5
-
34
-
-
33846903320
-
Deregulation of apoptosis in acute myeloid leukemia
-
Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007, 92:81-94.
-
(2007)
Haematologica
, vol.92
, pp. 81-94
-
-
Testa, U.1
Riccioni, R.2
-
35
-
-
84860726170
-
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
-
Traer E., MacKenzie R., Snead J., Agarwal A., Eiring A.M., O'Hare T., Druker B.J., Deininger M.W. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012, 26:1140-1143.
-
(2012)
Leukemia
, vol.26
, pp. 1140-1143
-
-
Traer, E.1
MacKenzie, R.2
Snead, J.3
Agarwal, A.4
Eiring, A.M.5
O'Hare, T.6
Druker, B.J.7
Deininger, M.W.8
-
36
-
-
0036233985
-
Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1
-
Ungureanu D., Saharinen P., Junttila I., Hilton D.J., Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell Biol. 2002, 22:3316-3326.
-
(2002)
Mol. Cell Biol.
, vol.22
, pp. 3316-3326
-
-
Ungureanu, D.1
Saharinen, P.2
Junttila, I.3
Hilton, D.J.4
Silvennoinen, O.5
-
37
-
-
79959255983
-
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis
-
Unterkircher T., Cristofanon S., Vellanki S.H., Nonnenmacher L., Karpel-Massler G., Wirtz C.R., Debatin K.M., Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin. Cancer Res. 2011, 17:4019-4030.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 4019-4030
-
-
Unterkircher, T.1
Cristofanon, S.2
Vellanki, S.H.3
Nonnenmacher, L.4
Karpel-Massler, G.5
Wirtz, C.R.6
Debatin, K.M.7
Fulda, S.8
-
38
-
-
0028172868
-
P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
-
Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84:3148-3157.
-
(1994)
Blood
, vol.84
, pp. 3148-3157
-
-
Wattel, E.1
Preudhomme, C.2
Hecquet, B.3
Vanrumbeke, M.4
Quesnel, B.5
Dervite, I.6
Morel, P.7
Fenaux, P.8
-
39
-
-
0023685838
-
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage
-
Willson J.K., Fischer P.H., Tutsch K., Alberti D., Simon K., Hamilton R.D., Bruggink J., Koeller J.M., Tormey D.C., Earhart R.H., Ranhsoky A., Trump D.L. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res. 1988, 48:5585-5590.
-
(1988)
Cancer Res.
, vol.48
, pp. 5585-5590
-
-
Willson, J.K.1
Fischer, P.H.2
Tutsch, K.3
Alberti, D.4
Simon, K.5
Hamilton, R.D.6
Bruggink, J.7
Koeller, J.M.8
Tormey, D.C.9
Earhart, R.H.10
Ranhsoky, A.11
Trump, D.L.12
-
40
-
-
0027960678
-
Kinetic analysis of the intracellular conjugation of monochlorobimane by IC-21 murine macrophage glutathione-S-transferase
-
Young P.R., ConnorsWhite A.L., Dzido G.A. Kinetic analysis of the intracellular conjugation of monochlorobimane by IC-21 murine macrophage glutathione-S-transferase. Biochim. Biophys. Acta. 1994, 1201:461-465.
-
(1994)
Biochim. Biophys. Acta.
, vol.1201
, pp. 461-465
-
-
Young, P.R.1
ConnorsWhite, A.L.2
Dzido, G.A.3
-
41
-
-
84872264689
-
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines
-
Zhao W., Du Y., Ho W.T., Fu X., Zhao Z.J. JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp. Hematol. Oncol. 2012, 1:15.
-
(2012)
Exp. Hematol. Oncol.
, vol.1
, pp. 15
-
-
Zhao, W.1
Du, Y.2
Ho, W.T.3
Fu, X.4
Zhao, Z.J.5
|